Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: Antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups

JSHCT GVHD Working Group

研究成果: Contribution to journalArticle査読

33 被引用数 (Scopus)

抄録

Graft-versus-host disease-free relapse-free survival, which is defined as the absence of grade III-IV acute graft-versus-host disease, systemically treated chronic graft-versus-host disease, relapse, and death, is a novel, meaningful composite end point for clinical trials. To characterize risk factors and differences in graft-versus-host disease-free relapse-free survival according to a variety of graft sources, we analyzed 23, 302 patients with hematologic malignancy that had a first allogeneic transplantation from 2000 through 2013 using the Japanese national transplant registry database. The 1-year graft-versus-host disease-free relapsefree survival rate was 41% in all patients. The rate was higher after bone marrow transplantation than after peripheral blood stem cell transplantation due to the lower risks of III-IV acute and chronic graft-versus-host disease. The rate was highest after HLA-matched sibling bone marrow transplantation. The rate after single cord blood transplantation was comparable to that after HLA-matched unrelated bone marrow transplantation among patients aged 20 years or under, and was comparable or better than other alternative graft sources among patients aged 21 years or over, due to the low risk of chronic graft-versus-host disease. Other factors associated with better graft-versus-host disease-free relapse-free survival include female patients, antithymocyte globulin prophylaxis (for standard-risk disease), recent years of transplantation, sex combinations other than from a female donor to a male patient, the absence of prior autologous transplantation, myeloablative conditioning, negative cytomegalovirus serostatus, and tacrolimus-based prophylaxis. These results provide important information to guide the choice of graft sources and are benchmarks for future graft-versus-host disease prophylaxis studies.

本文言語英語
ページ(範囲)1592-1602
ページ数11
ジャーナルHaematologica
101
12
DOI
出版ステータス出版済み - 2016

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: Antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル